BioSpace News Archive

– Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting –

National Study Finds 7 Percent Increase in Physician Job Openings

36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and molecular response

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 156,100 shares of its common stock to 93 new employees under Sage’s 2016 Inducement Equity Plan.

Global survey report identifies legacy infrastructure, succession challenges and regulatory change as top risks for businesses in the digital age

- Cardiologs, a medtech company transforming cardiac diagnostics using medical-grade artificial intelligence (AI) and cloud technology, announced today that co-founder and CEO, Yann Fleureau, has been named one of MIT Technology Review’s Innovators Under 35 Europe 2018.

In Dubai today, cardiologists, researchers, policymakers and health leaders came together at the launch of the World Heart Federation’s World Congress of Cardiology and Cardiovascular Health 2018.

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional’s fit set.

- Berkeley Lights, Inc. (BLI), a leader in digital cell biology, announced today the release of a plasma B cell antibody discovery workflow for use on the Beacon Optofluidic Platform.

New analysis of randomized clinical trial data for reSET demonstrate two-fold increase in abstinence and treatment retention for patients with Substance Use Disorder; highlight significant dose/response relationship